Amycretin vs Mounjaro: Which is Better for Weight Loss?
The weight loss medication landscape is evolving fast, with new drugs offering powerful results for patients struggling with obesity and related conditions. Two of the most talked-about names right now are Amycretin and Mounjaro (Tirzepatide). But which one is better? Let’s dive into the science, results, and how they compare.
What Are Amycretin and Mounjaro?
Amycretin is an experimental weight loss drug currently under development by Novo Nordisk, the makers of Wegovy and Ozempic. It is a dual agonist that targets GLP-1 and amylin receptors, both of which play a role in appetite regulation and digestion.
Mounjaro (generic name: Tirzepatide) is developed by Eli Lilly and already licensed for Type 2 diabetes, with growing off-label use for weight loss. It is also a dual agonist, targeting GLP-1 and GIP receptors.
Both drugs belong to a new generation of hormone-based weight loss treatments that work by reducing appetite and slowing down gastric emptying.
How Do They Work?
- Amycretin mimics the effects of GLP-1 (glucagon-like peptide-1) and amylin, a hormone involved in satiety and slowing gastric emptying. By targeting both, it may boost weight loss while potentially reducing gut-related side effects.
Mounjaro mimics GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), which together enhance insulin secretion, reduce appetite, and improve blood sugar control.
Weight Loss Results Compared
| Drug | Average Weight Loss | Trial Duration |
| Amycretin | 24.3% body weight | 36 weeks |
| Mounjaro | 16% body weight | 72weeks |
Amycretin’s results after just 36 weeks are already comparable, making it a strong contender once longer trials are complete.
Side Effects: Amycretin vs Mounjaro
Amycretin Side Effects:
- Nausea (27%)
- Diarrhoea (20%)
- Vomiting (11%)
- Fatigue (23%)
- Headache (16%)
Amycretin may cause fewer gastrointestinal issues due to its amylin component, which acts on the brain to enhance satiety rather than primarily targeting the gut.
Mounjaro Side Effects:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Injection site reactions
Mounjaro side effects are typical of other GLP-1 agonists but can be managed with proper dose monitoring.
Which Is Safer?
Both drugs appear safe and well-tolerated in clinical trials. However, Amycretin is still undergoing studies and has not yet been approved. Mounjaro, on the other hand, is already licensed for diabetes and used off-label for weight loss with prescriber oversight.
Availability in the UK
- Mounjaro is already available via private clinics in the UK for weight loss under off-label use.
Amycretin is expected to launch before 2030, pending successful completion of clinical trials.
Final Verdict: Which Is Better?
It’s still early days for Amycretin, but it holds enormous promise thanks to its dual action and impressive early results. Mounjaro, however, is currently the stronger option based on availability, longer-term trial data, and higher total weight loss outcomes.
If you’re seeking proven, medically supervised weight loss treatment today, Mounjaro is the better choice.
But keep your eye on Amycretin it could very well redefine the future of weight loss medications.
Interested in starting Mounjaro now or registering interest for Amycretin when it launches?
Visit MedCare Health Clinic to book your private weight loss consultation or join our Amycretin early access list today.